vaccine development

By Targets:	AP-1 (1) Biochemical Assay Reagents (1) Endogenous Metabolite (2) HPV (1) Interleukin Related (1) Isotope-Labeled Compounds (1) JNK (1) Liposome (5) MDM-2/p53 (1) MHC (3) mRNA (1) NF-κB (1) p38 MAPK (1) PPAR (1) SARS-CoV (2) Sirtuin (1) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (6) Infection (7) Inflammation/Immunology (4) Metabolic Disease (2)
Oligonucleotides:	Antigens (1) Pegylated Lipids (1) CpG ODNs (1) mRNA (1) Cationic Lipids (3)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131119

Dimethyldioctadecylammonium bromide Dioctadecyldimethylammonium bromide; DODAB	Liposome	Others
Dimethyldioctadecylammonium bromide is a synthetic cationic lipid commonly used in gene delivery and vaccine development. Also known as DODAB or DDAB, it consists of a positively charged ammonium head group and two long hydrophobic tails. These properties make it useful for forming liposomes and other lipid-based nanoparticles that can efficiently deliver genetic material into cells. In addition to its applications in biotechnology, DDAB is also used in surfactants, emulsifiers and fabric softeners. However, due to its potential toxicity and irritation, extreme care should be taken when handling DDAB.

HY-153083

COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP) 1 Publications Verification	mRNA SARS-CoV	Infection
COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) is an mRNA encoding the SARS-CoV-2 spike protein with enhanced performance via chemical modification. COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) replaces natural uridine (UTP) with N1-Me-Pseudo UTP, which effectively reduces immunogenicity and improves stability and translation efficiency. The 3' UTR of COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) optimizes AU-rich elements through HuR anchor sites, exhibiting higher translation efficiency. COVID-19 Spike Protein mRNA is widely used in COVID-19-related scientific research and vaccine development .

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-145795

OF-02	Liposome	Others
OF-02 is an ionizable lipid for mRNA delivery and a key component of lipid nanoparticles (LNPs). OF-02 is protonated in the acidic endosomal environment to promote endosomal escape of mRNA and efficiently induce protein expression in target cells. OF-02 relies on the pH-responsive membrane fusion properties to form a complex with mRNA and destroy the endosomal membrane structure to achieve mRNA release in the cytoplasm. OF-02 is mainly used in the development of mRNA vaccines, gene editing, and protein replacement therapy[1][2][3].

HY-165126

Schizophyllan SPG	Endogenous Metabolite Sirtuin JNK p38 MAPK PPAR AP-1	Infection Metabolic Disease Inflammation/Immunology Cancer
Schizophyllan (SPG) is an orally active extracellular β-glucan produced by the fungus Schizophyllum commune. Schizophyllan improves mitochondrial function and protects against metabolic liver injury by activating the SIRT3 pathway. Schizophyllan inhibits osteoclastogenesis and promotes osteoblast differentiation by suppressing the phosphorylation of JNK/p38, as well as downregulating PGC1β/PPARγ, c-Fos and NFATc1. Recognized via Dectin-1, schizophyllan enables precise delivery of oligonucleotide drugs and antigens to antigen-presenting cells, thus holding great potential in the treatment of inflammatory diseases and vaccine development .

HY-P2779

Microsomal aminopeptidase, Microorganism	Endogenous Metabolite	Metabolic Disease
Microsomal aminopeptidase, Microorganism is first reported from C. elegans. The Microsomal aminopeptidase, Microorganism is beneficial for the development of molecular vaccines against parasitic nematodes .

HY-P11058

OVA(250-264) OVAp	MHC	Cancer
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8 ⁺ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research .

HY-N9517

QS 7 QS 7 Api	Others	Inflammation/Immunology Cancer
QS 7 (QS 7 Api) is a triterpene saponin found in the bark of Quillaja saponaria and immune adjuvant with immune response potentiator activity. QS 7 can be used as vaccine adjuvant for the research of antitumor and antiviral vaccine development .

HY-134783

1,19-Bis(2-butyloctyl) 10-[[3-(dimethylamino)propyl](1-oxononyl)amino]nonadecanedioate	Liposome	Others
1,19-Bis(2-butyloctyl) 10-[[3-(dimethylamino)propyl](1-oxononyl)amino]nonadecanedioate is an excipient for vaccines. 1,19-Bis(2-butyloctyl) 10-[[3-(dimethylamino)propyl](1-oxononyl)amino]nonadecanedioate can be used for the research of the development of COVID-19 vaccines and drug delivery for gene therapy .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development* of an effective peptide-based antitumor vaccine .

HY-162726

GCS-11	Interleukin Related	Cancer
GCS-11 is a powerful natural killer T (NKT) cell agonist. It boosts the production of IFN-γ and IL-4, with a particular selectivity for IFN-γ. GCS-11 exhibits anticancer activity. GCS-11 has the potential for research into cancer immunotherapies or vaccine development as a promising adjuvant .

HY-158867

DOSPA (hydrochlorid)	Liposome	Infection
DOSPA hydrochlorid is a frequently utilized cationic lipid in the generation of Lipid Nanoparticles (LNPs) for the development of mRNA vaccines, including the COVID-19 vaccine.

HY-157183

HSMO9	Biochemical Assay Reagents	Inflammation/Immunology
HSMO9 is a (+)-methamphetamine (METH)-like hapten that can be coupled to a carrier protein. HSMO9 can be used in vaccine development .

HY-P10295

p53 (232-240)	MDM-2/p53	Cancer
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .

HY-144120

αGalCer-RBD	SARS-CoV	Infection
αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist . RBD: receptor-binding domain

HY-P3070

H2-D b restricted epitopes VSV Nucleoprotein (52-59)	MHC	Infection Others
H2-D b restricted epitopes VSV Nucleoprotein (52-59) is a 9-mer peptide derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). H2-D b restricted epitopes VSV Nucleoprotein (52-59) binds to MHC class I molecules and presents itself to CD8+ T cells, thereby activating cytotoxic T lymphocytes (CTLs), which can recognize and kill cells expressing the corresponding antigen. H2-D b restricted epitopes VSV Nucleoprotein (52-59) can be used in the development of CTL vaccines against Ebola virus .

HY-171239

Ste2Cys	Toll-like Receptor (TLR) NF-κB MHC	Others
Ste2Cys is a diacylglycerol cysteine-type immunologic adjuvant lipid molecule. Ste2Cys can bind to TLR2 and activate NF-κB signaling pathway. Ste2Cy can upregulate the expression of MHC II class molecules on the surface of mouse bone marrow-derived D1 dendritic cells. Ste2Cys can be used for research of the development of immunologic vaccines .

HY-W724291

Dimethyldioctadecylammonium-d3 bromide Dioctadecyldimethylammonium-d₃ bromide; DODAB-d₃	Isotope-Labeled Compounds Liposome	Others
Dimethyldioctadecylammonium-d₃ bromide (Dioctadecyldimethylammonium-d₃ bromide) is the deuterium labeled Dimethyldioctadecylammonium bromide (HY-131119). Dimethyldioctadecylammonium bromide is a synthetic cationic lipid commonly used in gene delivery and vaccine development. Also known as DODAB or DDAB, it consists of a positively charged ammonium head group and two long hydrophobic tails. These properties make it useful for forming liposomes and other lipid-based nanoparticles that can efficiently deliver genetic material into cells. In addition to its applications in biotechnology, DDAB is also used in surfactants, emulsifiers and fabric softeners. However, due to its potential toxicity and irritation, extreme care should be taken when handling DDAB.

Cat. No.	Product Name

HY-L105

Peptide Library	2,520 compounds
Peptides are a group of biologically active substances that are involved in various cellular functions of organisms. Peptides are often used in functional analysis, vaccine research and especially in the field of drug research and development. At present, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. MedChemExpress (MCE) offers a comprehensive collection of 2,520 peptides, including bioactive peptides, amino acid derivatives, and blocking peptides. MCE Peptide Library can be used for peptide library screening, peptide drug discovery, vaccine development, target verification, structural activity research, etc.

Peptide Library

2,520 compounds

Peptides are a group of biologically active substances that are involved in various cellular functions of organisms. Peptides are often used in functional analysis, vaccine research and especially in the field of drug research and development. At present, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain.

MedChemExpress (MCE) offers a comprehensive collection of 2,520 peptides, including bioactive peptides, amino acid derivatives, and blocking peptides. MCE Peptide Library can be used for peptide library screening, peptide drug discovery, vaccine development, target verification, structural activity research, etc.

HY-L172

Immunopotentiator Compound Library	140 compounds
Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines. MCE designs a unique collection of 140 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.

Immunopotentiator Compound Library

140 compounds

Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines.

MCE designs a unique collection of 140 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.

HY-L216

Polysaccharides Compound Library	68 compounds
Polysaccharides are long chains of carbohydrate molecules, consisting of multiple smaller monosaccharides. Polysaccharides are found mainly in natural sources such as plants, microorganisms, algae and animals. Polysaccharides have a large number of active functional groups, different chemical compositions and different molecular weight ranges, which determines their diversity in nature and structure. Also in the field of medical research, polysaccharides act as a class of functional compounds and thus play a role. For example, nanocarrier construction, immunomodulation and vaccine development, new strategies for antitumor therapy, tissue regeneration engineering applications and disease diagnosis. With the advancement of glycomics and synthetic biotechnology, human beings are moving from “knowing polysaccharides” to “designing polysaccharides”, which will provide innovative solutions for materials science, precision medicine and sustainable development. MCE offers 68 polysaccharides that can be used in biomedical studies.

Polysaccharides Compound Library

68 compounds

Polysaccharides are long chains of carbohydrate molecules, consisting of multiple smaller monosaccharides. Polysaccharides are found mainly in natural sources such as plants, microorganisms, algae and animals. Polysaccharides have a large number of active functional groups, different chemical compositions and different molecular weight ranges, which determines their diversity in nature and structure. Also in the field of medical research, polysaccharides act as a class of functional compounds and thus play a role. For example, nanocarrier construction, immunomodulation and vaccine development, new strategies for antitumor therapy, tissue regeneration engineering applications and disease diagnosis. With the advancement of glycomics and synthetic biotechnology, human beings are moving from “knowing polysaccharides” to “designing polysaccharides”, which will provide innovative solutions for materials science, precision medicine and sustainable development.

MCE offers 68 polysaccharides that can be used in biomedical studies.

HY-L110

Cyclic Peptide Library	97 compounds
Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs. MCE offers a unique collection of 97 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Cyclic Peptide Library

97 compounds

Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs.

MCE offers a unique collection of 97 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

HY-L073

Anti-Hepatitis C Virus Compound Library	391 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

391 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Type

HY-131119

Dimethyldioctadecylammonium bromide Dioctadecyldimethylammonium bromide; DODAB	Biochemical Assay Reagents
Dimethyldioctadecylammonium bromide is a synthetic cationic lipid commonly used in gene delivery and vaccine development. Also known as DODAB or DDAB, it consists of a positively charged ammonium head group and two long hydrophobic tails. These properties make it useful for forming liposomes and other lipid-based nanoparticles that can efficiently deliver genetic material into cells. In addition to its applications in biotechnology, DDAB is also used in surfactants, emulsifiers and fabric softeners. However, due to its potential toxicity and irritation, extreme care should be taken when handling DDAB.

Dimethyldioctadecylammonium bromide

Dioctadecyldimethylammonium bromide; DODAB

Biochemical Assay Reagents

Dimethyldioctadecylammonium bromide is a synthetic cationic lipid commonly used in gene delivery and vaccine development. Also known as DODAB or DDAB, it consists of a positively charged ammonium head group and two long hydrophobic tails. These properties make it useful for forming liposomes and other lipid-based nanoparticles that can efficiently deliver genetic material into cells. In addition to its applications in biotechnology, DDAB is also used in surfactants, emulsifiers and fabric softeners. However, due to its potential toxicity and irritation, extreme care should be taken when handling DDAB.

HY-145795

OF-02	Biochemical Assay Reagents
OF-02 is an ionizable lipid for mRNA delivery and a key component of lipid nanoparticles (LNPs). OF-02 is protonated in the acidic endosomal environment to promote endosomal escape of mRNA and efficiently induce protein expression in target cells. OF-02 relies on the pH-responsive membrane fusion properties to form a complex with mRNA and destroy the endosomal membrane structure to achieve mRNA release in the cytoplasm. OF-02 is mainly used in the development of mRNA vaccines, gene editing, and protein replacement therapy[1][2][3].

OF-02

Biochemical Assay Reagents

OF-02 is an ionizable lipid for mRNA delivery and a key component of lipid nanoparticles (LNPs). OF-02 is protonated in the acidic endosomal environment to promote endosomal escape of mRNA and efficiently induce protein expression in target cells. OF-02 relies on the pH-responsive membrane fusion properties to form a complex with mRNA and destroy the endosomal membrane structure to achieve mRNA release in the cytoplasm. OF-02 is mainly used in the development of mRNA vaccines, gene editing, and protein replacement therapy[1][2][3].

Cat. No.	Product Name	Target	Research Area

HY-P11058

OVA(250-264) OVAp	MHC	Cancer
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8 ⁺ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development* of an effective peptide-based antitumor vaccine .

HY-P5078

NPNA hexamer	Peptides	Infection
NPNA hexamer is a peptide. NPNA hexamer can be used for the research of malaria and the development of a sporozoite vaccine .

HY-P10295

p53 (232-240)	MDM-2/p53	Cancer
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .

HY-P3070

H2-D b restricted epitopes VSV Nucleoprotein (52-59)	MHC	Infection Others
H2-D b restricted epitopes VSV Nucleoprotein (52-59) is a 9-mer peptide derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). H2-D b restricted epitopes VSV Nucleoprotein (52-59) binds to MHC class I molecules and presents itself to CD8+ T cells, thereby activating cytotoxic T lymphocytes (CTLs), which can recognize and kill cells expressing the corresponding antigen. H2-D b restricted epitopes VSV Nucleoprotein (52-59) can be used in the development of CTL vaccines against Ebola virus .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N9517

QS 7 QS 7 Api	Triterpenes Structural Classification Quillajaceae Quillaja saponaria Molina Terpenoids Plants Pentacyclic Triterpenoids Source Classification	Others
QS 7 (QS 7 Api) is a triterpene saponin found in the bark of Quillaja saponaria and immune adjuvant with immune response potentiator activity. QS 7 can be used as vaccine adjuvant for the research of antitumor and antiviral vaccine development .

Cat. No.	Product Name	Chemical Structure

HY-W724291

Dimethyldioctadecylammonium-d3 bromide
Dimethyldioctadecylammonium-d₃ bromide (Dioctadecyldimethylammonium-d₃ bromide) is the deuterium labeled Dimethyldioctadecylammonium bromide (HY-131119). Dimethyldioctadecylammonium bromide is a synthetic cationic lipid commonly used in gene delivery and vaccine development. Also known as DODAB or DDAB, it consists of a positively charged ammonium head group and two long hydrophobic tails. These properties make it useful for forming liposomes and other lipid-based nanoparticles that can efficiently deliver genetic material into cells. In addition to its applications in biotechnology, DDAB is also used in surfactants, emulsifiers and fabric softeners. However, due to its potential toxicity and irritation, extreme care should be taken when handling DDAB.

Dimethyldioctadecylammonium-d3 bromide

Dimethyldioctadecylammonium-d₃ bromide (Dioctadecyldimethylammonium-d₃ bromide) is the deuterium labeled Dimethyldioctadecylammonium bromide (HY-131119). Dimethyldioctadecylammonium bromide is a synthetic cationic lipid commonly used in gene delivery and vaccine development. Also known as DODAB or DDAB, it consists of a positively charged ammonium head group and two long hydrophobic tails. These properties make it useful for forming liposomes and other lipid-based nanoparticles that can efficiently deliver genetic material into cells. In addition to its applications in biotechnology, DDAB is also used in surfactants, emulsifiers and fabric softeners. However, due to its potential toxicity and irritation, extreme care should be taken when handling DDAB.

Cat. No.	Product Name		Classification

HY-131119

Dimethyldioctadecylammonium bromide Dioctadecyldimethylammonium bromide; DODAB		Cationic Lipids
Dimethyldioctadecylammonium bromide is a synthetic cationic lipid commonly used in gene delivery and vaccine development. Also known as DODAB or DDAB, it consists of a positively charged ammonium head group and two long hydrophobic tails. These properties make it useful for forming liposomes and other lipid-based nanoparticles that can efficiently deliver genetic material into cells. In addition to its applications in biotechnology, DDAB is also used in surfactants, emulsifiers and fabric softeners. However, due to its potential toxicity and irritation, extreme care should be taken when handling DDAB.

HY-153083

COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP) 1 Publications Verification		mRNA Antigens
COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) is an mRNA encoding the SARS-CoV-2 spike protein with enhanced performance via chemical modification. COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) replaces natural uridine (UTP) with N1-Me-Pseudo UTP, which effectively reduces immunogenicity and improves stability and translation efficiency. The 3' UTR of COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) optimizes AU-rich elements through HuR anchor sites, exhibiting higher translation efficiency. COVID-19 Spike Protein mRNA is widely used in COVID-19-related scientific research and vaccine development .

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101		CpG ODNs
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-145795

OF-02		Cationic Lipids
OF-02 is an ionizable lipid for mRNA delivery and a key component of lipid nanoparticles (LNPs). OF-02 is protonated in the acidic endosomal environment to promote endosomal escape of mRNA and efficiently induce protein expression in target cells. OF-02 relies on the pH-responsive membrane fusion properties to form a complex with mRNA and destroy the endosomal membrane structure to achieve mRNA release in the cytoplasm. OF-02 is mainly used in the development of mRNA vaccines, gene editing, and protein replacement therapy[1][2][3].

HY-134783

1,19-Bis(2-butyloctyl) 10-[[3-(dimethylamino)propyl](1-oxononyl)amino]nonadecanedioate		Pegylated Lipids
1,19-Bis(2-butyloctyl) 10-[[3-(dimethylamino)propyl](1-oxononyl)amino]nonadecanedioate is an excipient for vaccines. 1,19-Bis(2-butyloctyl) 10-[[3-(dimethylamino)propyl](1-oxononyl)amino]nonadecanedioate can be used for the research of the development of COVID-19 vaccines and drug delivery for gene therapy .

HY-158867

DOSPA (hydrochlorid)		Cationic Lipids
DOSPA hydrochlorid is a frequently utilized cationic lipid in the generation of Lipid Nanoparticles (LNPs) for the development of mRNA vaccines, including the COVID-19 vaccine.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

vaccine development

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products